Payment overview · 2025
General Payments
$1,626.14
74 reported records · 25 companies
Healthcare provider profile · identity verified
Kishor Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ROCKY RIVER, OH · NPI 1073613626
Verified facts
What the public records show
CMS Open Payments records show Kishor Patel, MD received $1,626.14 in general payments during 2025 across 74 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 316 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1078 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 316 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1078 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $281.43 | 17.3% | 11 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $167.49 | 10.3% | 6 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $138.54 | 8.5% | 10 | 2025 |
| Olympus America Inc. | Unresolved — no canonical attribution shown | $138.31 | 8.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $108.20 | 6.7% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $106.24 | 6.5% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $102.21 | 6.3% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $69.57 | 4.3% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $56.00 | 3.4% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.68 | 3.4% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.19 | 3.3% | 3 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $49.13 | 3.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.52 | 3.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.32 | 2.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $33.08 | 2.0% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.16 | 1.5% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $19.92 | 1.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.86 | 1.2% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $19.62 | 1.2% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $19.16 | 1.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.99 | 1.2% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.86 | 1.0% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$16.24 | 1.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.34 | 0.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.08 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,614.58 | 73 |
| Education | $11.56 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $269.87 | 10 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $153.42 | 5 | 2025 |
Source payment records
|
|||||
| iTIND System Normalized: itind system |
Device | Olympus America Inc. | $138.31 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $129.95 | 8 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $102.21 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $72.43 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $60.87 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $59.31 | 3 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $57.11 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $56.00 | 3 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $54.68 | 2 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $49.13 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.89 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $48.52 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $48.42 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.91 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.91 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $36.78 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.32 | 2 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $19.16 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1078 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 55 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 67 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
61 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
316 | 60 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1078 | 152 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
67 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
316 | 60 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
62 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1078 | 152 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2143 | 387 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1408 | 231 |
| Amlodipine Besylate | Amlodipine Besylate | 1379 | 276 |
| Eliquis | Apixaban | 1078 | 152 |
| Furosemide | Furosemide | 1055 | 205 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1041 | 206 |
| Gabapentin | Gabapentin | 885 | 126 |
| Potassium Chloride | Potassium Chloride | 789 | 168 |
| Metoprolol Tartrate | Metoprolol Tartrate | 714 | 137 |
| Sertraline Hcl | Sertraline Hcl | 655 | 107 |
| Metformin Hcl | Metformin Hcl | 648 | 127 |
| Metoprolol Succinate | Metoprolol Succinate | 643 | 164 |
| Mirtazapine | Mirtazapine | 638 | 104 |
| Tamsulosin Hcl | Tamsulosin Hcl | 622 | 119 |
| Lisinopril | Lisinopril | 616 | 142 |
| Losartan Potassium | Losartan Potassium | 540 | 105 |
| Trazodone Hcl | Trazodone Hcl | 536 | 93 |
| Omeprazole | Omeprazole | 483 | 93 |
| Donepezil Hcl | Donepezil Hcl | 475 | 68 |
| Buspirone Hcl | Buspirone Hcl | 460 | 72 |
| Escitalopram Oxalate | Escitalopram Oxalate | 442 | 61 |
| Clopidogrel | Clopidogrel Bisulfate | 421 | 72 |
| Allopurinol | Allopurinol | 391 | 62 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 388 | 72 |
| Simvastatin | Simvastatin | 365 | 77 |
| Carvedilol | Carvedilol | 357 | 68 |
| Memantine Hcl | Memantine Hcl | 325 | 54 |
| Jardiance | Empagliflozin | 316 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 315 | 75 |
| Spironolactone | Spironolactone | 306 | 60 |
| Divalproex Sodium | Divalproex Sodium | 301 | 45 |
| Levetiracetam | Levetiracetam | 292 | 35 |
| Humalog Kwikpen U-100 | Insulin Lispro | 264 | 45 |
| Montelukast Sodium | Montelukast Sodium | 263 | 60 |
| Torsemide | Torsemide | 262 | 51 |
| Xarelto | Rivaroxaban | 262 | 40 |
| Januvia | Sitagliptin Phosphate | 260 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 259 | 108 |
| Duloxetine Hcl | Duloxetine Hcl | 256 | 50 |
| Warfarin Sodium | Warfarin Sodium | 240 | 31 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 222 | 30 |
| Baclofen | Baclofen | 214 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 206 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 204 | 61 |
| Midodrine Hcl | Midodrine Hcl | 203 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 201 | 24 |
| Azithromycin | Azithromycin | 198 | 131 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 198 | 68 |
| Latanoprost | Latanoprost | 198 | 44 |
| Famotidine | Famotidine | 184 | 36 |
| Myrbetriq | Mirabegron | 184 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 183 | 34 |
| Prednisone | Prednisone | 183 | 56 |
| Atenolol | Atenolol | 179 | 38 |
| Celecoxib | Celecoxib | 176 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 175 | 38 |
| Finasteride | Finasteride | 174 | 43 |
| Ondansetron Hcl | Ondansetron Hcl | 166 | 95 |
| Citalopram Hbr | Citalopram Hydrobromide | 164 | 25 |
| Lactulose | Lactulose | 159 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 153 | 67 |
| Nystatin | Nystatin | 152 | 65 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 148 | 48 |
| Ezetimibe | Ezetimibe | 147 | 32 |
| Risperidone | Risperidone | 146 | 16 |
| Meloxicam | Meloxicam | 145 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 143 | 25 |
| Olanzapine | Olanzapine | 141 | 22 |
| Meclizine Hcl | Meclizine Hcl | 130 | 29 |
| Cephalexin | Cephalexin | 128 | 81 |
| Paroxetine Hcl | Paroxetine Hcl | 126 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 124 | 74 |
| Amiodarone Hcl | Amiodarone Hcl | 122 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 122 | 89 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 122 | 43 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 120 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 118 | 71 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 118 | 54 |
| Methylprednisolone | Methylprednisolone | 117 | 85 |
| Oxybutynin Chloride | Oxybutynin Chloride | 114 | 19 |
| Enoxaparin Sodium | Enoxaparin Sodium | 113 | suppressed |
| Glimepiride | Glimepiride | 112 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 109 | 20 |
| Aripiprazole | Aripiprazole | 107 | 16 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 106 | 52 |
| Alendronate Sodium | Alendronate Sodium | 100 | 26 |
| Sucralfate | Sucralfate | 99 | 18 |
| Digoxin | Digoxin | 94 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 94 | 37 |
| Bupropion Xl | Bupropion Hcl | 92 | 22 |
| Glipizide | Glipizide | 87 | 19 |
| Entresto | Sacubitril/Valsartan | 84 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 84 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 84 | 52 |
| Lidocaine | Lidocaine | 82 | 15 |
| Lorazepam | Lorazepam | 79 | 38 |
| Propranolol Hcl | Propranolol Hcl | 77 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 77 | 15 |
| Metformin Hcl Er | Metformin Hcl | 76 | 18 |
| Linzess | Linaclotide | 75 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 74 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 74 | 14 |
| Ramipril | Ramipril | 74 | 17 |
| Amoxicillin | Amoxicillin | 73 | 51 |
| Diclofenac Sodium | Diclofenac Sodium | 73 | 29 |
| Dicyclomine Hcl | Dicyclomine Hcl | 71 | suppressed |
| Nifedipine Er | Nifedipine | 71 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 21 |
| Tradjenta | Linagliptin | 70 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 69 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 68 | suppressed |
| Levofloxacin | Levofloxacin | 67 | 38 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 65 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 65 | 13 |
| Klayesta | Nystatin | 65 | 30 |
| Clonidine Hcl | Clonidine Hcl | 63 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 63 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 63 | 13 |
| Naproxen | Naproxen | 63 | 21 |
| Trulicity | Dulaglutide | 62 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 61 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 61 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 61 | 14 |
| Nitroglycerin | Nitroglycerin | 58 | 34 |
| Topiramate | Topiramate | 58 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 58 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 55 | suppressed |
| Ozempic | Semaglutide | 55 | 11 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 54 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 53 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 52 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 52 | 16 |
| Sevelamer Carbonate | Sevelamer Carbonate | 52 | suppressed |
| Budesonide | Budesonide | 51 | suppressed |
| Colchicine | Colchicine | 51 | 17 |
| Novolog Flexpen | Insulin Aspart | 51 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 50 | 11 |
| Hydrocortisone | Hydrocortisone | 50 | 25 |
| Fluconazole | Fluconazole | 49 | 31 |
| Clobetasol Propionate | Clobetasol Propionate | 48 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 47 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 46 | 13 |
| Loperamide | Loperamide Hcl | 46 | 36 |
| Synthroid | Levothyroxine Sodium | 46 | 14 |
| Trintellix | Vortioxetine Hydrobromide | 46 | suppressed |
| Ketoconazole | Ketoconazole | 45 | 20 |
| Lamotrigine | Lamotrigine | 45 | 11 |
| Methocarbamol | Methocarbamol | 45 | 14 |
| Trospium Chloride | Trospium Chloride | 45 | 11 |
| Glipizide Er | Glipizide | 43 | 12 |
| Mometasone Furoate | Mometasone Furoate | 42 | 25 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 41 | 12 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 40 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | 11 |
| Bumetanide | Bumetanide | 39 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 39 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 11 |
| Methotrexate | Methotrexate Sodium | 39 | suppressed |
| Primidone | Primidone | 39 | suppressed |
| Procrit | Epoetin Alfa | 39 | suppressed |
| Timolol Maleate | Timolol Maleate | 39 | suppressed |
| Verapamil Er | Verapamil Hcl | 39 | suppressed |
| Amantadine | Amantadine Hcl | 38 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Ivermectin | Ivermectin | 38 | 35 |
| Valproic Acid | Valproic Acid | 38 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 38 | suppressed |
| Calcitriol | Calcitriol | 36 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 36 | 20 |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Humalog | Insulin Lispro | 35 | 14 |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 35 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 34 | 13 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 34 | 26 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | 11 |
| Azelastine Hcl | Azelastine Hcl | 32 | 15 |
| Estradiol | Estradiol | 32 | 14 |
| Diltiazem Hcl | Diltiazem Hcl | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Valsartan | Valsartan | 31 | 13 |
| Venlafaxine Hcl | Venlafaxine Hcl | 31 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 29 | 21 |
| Nadolol | Nadolol | 29 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 28 | 14 |
| Bethanechol Chloride | Bethanechol Chloride | 28 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 28 | suppressed |
| Azathioprine | Azathioprine | 27 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 27 | 12 |
| Methimazole | Methimazole | 27 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Scopolamine | Scopolamine | 27 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 27 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 26 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 26 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Tobramycin | Tobramycin | 26 | 22 |
| Carbamazepine Er | Carbamazepine | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 15 |
| Incruse Ellipta | Umeclidinium Bromide | 25 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 24 | suppressed |
| Anastrozole | Anastrozole | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 23 | 11 |
| Fluocinonide | Fluocinonide | 23 | suppressed |
| Metolazone | Metolazone | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Haloperidol | Haloperidol | 22 | suppressed |
| Leflunomide | Leflunomide | 22 | suppressed |
| Ranolazine Er | Ranolazine | 22 | suppressed |
| Acetic Acid | Acetic Acid | 21 | suppressed |
| Calcium Acetate | Calcium Acetate | 21 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 21 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 21 | suppressed |
| Insulin Lispro | Insulin Lispro | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 21 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 20 | suppressed |
| Clotrimazole | Clotrimazole | 20 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 20 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Clozapine | Clozapine | 19 | suppressed |
| Cyclosporine | Cyclosporine | 19 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 19 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | 11 |
| Bupropion Hcl | Bupropion Hcl | 18 | suppressed |
| Desoximetasone | Desoximetasone | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Letrozole | Letrozole | 18 | suppressed |
| Mirabegron Er | Mirabegron | 18 | suppressed |
| Nystop | Nystatin | 18 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 11 |
| Nyamyc | Nystatin | 17 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 17 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 16 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 16 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 16 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | suppressed |
| Cimetidine | Cimetidine | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | 14 |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 13 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Paliperidone Er | Paliperidone | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 13 | suppressed |
| Trimethoprim | Trimethoprim | 13 | suppressed |
| Alogliptin | Alogliptin Benzoate | 12 | suppressed |
| Alphagan P | Brimonidine Tartrate | 12 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Clindamycin Phosphate-D5w | Clindamycin Phosphate/D5w | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Ertapenem | Ertapenem Sodium | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Methazolamide | Methazolamide | 11 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 11 | suppressed |
| Tacrolimus | Tacrolimus | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,626.14 · 74 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AMYVID, Auvelity, BREZTRI, CAMZYOS, CAPLYTA, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, GIMOTI, GVOKE HYPOPEN, INGREZZA, KISUNLA, Korlym, MOUNJARO, NURTEC ODT, ONPATTRO, OTEZLA, Ozempic, RECORLEV, REPATHA, REXULTI, REZDIFFRA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UNITHROID, VERQUVO, VOWST, Wegovy, ZENPEP, ZEPBOUND, iTIND System | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error